Article Abstract

Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?

Authors: Xavier Pivot, David G. Cox, Joseph Gligorov


All medical oncologists who attended the plenary session at ASCO 2005 remember the emotion provoked by the early release of the dramatic benefit resulting from the use of adjuvant trastuzumab (1,2).